Analytical Data
-
Gene name
IGFBP-4
- Application
-
Alternative Names
BP4; HT29-IGFBP; IBP4
-
Species
Chicken
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
NM_204353.1
-
Expression Region
Ala20~Met260
-
Protein Length
Partial
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like growth factor binding protein 4 (IGFBP-4) is a member of the IGFBP family, which plays a crucial role in the regulation of insulin-like growth factors (IGFs), themselves vital for growth and development in mammals. Research has shown that IGFBP-4 can modulate the availability and activity of IGFs, thus influencing numerous biological processes, including cell proliferation, differentiation, and apoptosis. Elevated levels of IGFBP-4 have been implicated in various pathological conditions, such as cancer, diabetes, and cardiovascular diseases, making it a key target for therapeutic interventions. The production of recombinant IGFBP-4 protein in vitro allows for detailed studies of its structure-function relationships and biological activities. By employing recombinant DNA technology, scientists can generate large quantities of this protein, facilitating investigations into its role in physiological and pathological processes. Understanding the molecular mechanisms underlying IGFBP-4's functions may open new avenues for diagnostic and therapeutic strategies, particularly in diseases where IGF signaling is disrupted. Hence, the study of recombinant IGFBP-4 protein is essential for elucidating its potential as a biomarker and therapeutic target, reinforcing its significance in both clinical and research settings.
